Home・Akciju saraksts・Intellia Therapeutics Inc

Intellia Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

10.69 -3.61

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

10.63

Max

10.75

Galvenie mērījumi
By Trading Economics
Ienākumi	106M -96M
Pārdošana	-8M 15M
EPS	-0.81
Peļņas marža	-639.494
Darbinieki	377
EBITDA	1.4M -94M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+77.15% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 6. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-159M 1.5B
Iepriekšējā atvēršanas cena	14.3
Iepriekšējā slēgšanas cena	10.69

Ziņu noskaņojums

By Acuity

18%

82%

28 / 340 Rangs Healthcare

Intellia Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 31. jūl. 20:06 UTC

Correlated Moves

Intellia Therapeutics Inc shares are lower today, reflecting broader sector pressures amid rising Treasury yields and inflation concerns.

2026. g. 30. jūl. 17:57 UTC

Correlated Moves

News

Shares higher today, supported by Invesco WilderHill Clean Energy ETF.

2026. g. 29. jūl. 23:31 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive sentiment in small-cap stocks amid broader market trends and the Fed's interest rate decision.

2026. g. 28. jūl. 18:36 UTC

Intellia Therapeutics Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.

2026. g. 27. jūl. 23:46 UTC

Intellia Therapeutics shares are higher in after-market trading, amid positive sentiment in European markets as the DAX rises.

2026. g. 25. jūl. 00:02 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in after-market trading, reflecting positive movement in the biotechnology sector amid broader market stability.

2026. g. 24. jūl. 13:31 UTC

Correlated Moves

Intellia Therapeutics Inc shares are higher in pre-market trading, advancing since Thursday's close despite being significantly below its 20-day moving average.

2026. g. 23. jūl. 19:16 UTC

Intellia Therapeutics shares are higher Thursday, recovering from an earlier pullback amid a challenging tech sector backdrop following disappointing earnings from major companies.

2026. g. 22. jūl. 23:56 UTC

Intellia Therapeutics Inc shares are higher in after-market trading, though they remain below their 20-day moving average and near the lower end of their one-month range.

2026. g. 21. jūl. 22:46 UTC

Intellia Therapeutics Inc shares are lower in after-market trading amid a lack of specific company news. The stock remains below its 20-day moving average.

2026. g. 20. jūl. 23:41 UTC

Correlated Moves

Intellia Therapeutics shares are higher in after-market trading, reflecting a positive shift amid broader market trends and correlated gains in Beam Therapeutics.

Salīdzinājums

Cenas izmaiņa

Intellia Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

77.15% augšup

Prognoze 12 mēnešiem

Vidējais 18.92 USD 77.15%

Augstākais 49 USD

Zemākais 8 USD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Intellia Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

14 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 14 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Intellia Therapeutics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

28 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.